Iovance Biotherapeutics, Inc. (0JDK.L)
USD 7.6
(-2.69%)
USD 7.6
(-2.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -460.55 Million USD | -15.46% |
| 2022 | -398.87 Million USD | -16.39% |
| 2021 | -342.7 Million USD | -30.83% |
| 2020 | -261.93 Million USD | -26.62% |
| 2019 | -206.87 Million USD | -61.29% |
| 2018 | -128.25 Million USD | -38.09% |
| 2017 | -92.87 Million USD | -73.15% |
| 2016 | -53.63 Million USD | -92.53% |
| 2015 | -27.86 Million USD | -131.38% |
| 2014 | -12.04 Million USD | -101.19% |
| 2013 | -5.98 Million USD | 26.41% |
| 2012 | -8.13 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -117.72 Million USD | 2.91% |
| 2024 Q2 | -101.91 Million USD | 13.43% |
| 2023 Q2 | -110.08 Million USD | 0.69% |
| 2023 Q3 | -118.36 Million USD | -7.52% |
| 2023 Q4 | -121.25 Million USD | -2.45% |
| 2023 Q1 | -110.85 Million USD | -3.57% |
| 2023 FY | -460.55 Million USD | -15.46% |
| 2022 Q4 | -107.03 Million USD | -6.61% |
| 2022 Q3 | -100.39 Million USD | -0.66% |
| 2022 Q2 | -99.73 Million USD | -8.75% |
| 2022 Q1 | -91.71 Million USD | 7.79% |
| 2022 FY | -398.87 Million USD | -16.39% |
| 2021 Q4 | -99.46 Million USD | -15.33% |
| 2021 Q1 | -75.57 Million USD | -10.27% |
| 2021 Q2 | -81.42 Million USD | -7.75% |
| 2021 FY | -342.7 Million USD | -30.83% |
| 2021 Q3 | -86.24 Million USD | -5.91% |
| 2020 Q1 | -70.81 Million USD | -8.75% |
| 2020 Q3 | -58.96 Million USD | 7.33% |
| 2020 FY | -261.93 Million USD | -26.62% |
| 2020 Q4 | -68.53 Million USD | -16.23% |
| 2020 Q2 | -63.62 Million USD | 10.14% |
| 2019 Q2 | -50.16 Million USD | -25.46% |
| 2019 Q1 | -39.98 Million USD | -14.43% |
| 2019 FY | -206.87 Million USD | -61.29% |
| 2019 Q4 | -65.11 Million USD | -26.16% |
| 2019 Q3 | -51.61 Million USD | -2.88% |
| 2018 Q1 | -26.87 Million USD | -3.09% |
| 2018 Q3 | -35.06 Million USD | -11.73% |
| 2018 Q2 | -31.37 Million USD | -16.75% |
| 2018 FY | -128.25 Million USD | -38.09% |
| 2018 Q4 | -34.94 Million USD | 0.33% |
| 2017 Q1 | -20.88 Million USD | -225.16% |
| 2017 Q3 | -22.34 Million USD | 5.25% |
| 2017 Q4 | -26.07 Million USD | -16.69% |
| 2017 FY | -92.87 Million USD | -73.15% |
| 2017 Q2 | -23.58 Million USD | -12.93% |
| 2016 Q4 | -6.42 Million USD | 66.16% |
| 2016 Q1 | -7.01 Million USD | 17.33% |
| 2016 Q3 | -18.97 Million USD | -61.84% |
| 2016 FY | -53.63 Million USD | -92.53% |
| 2016 Q2 | -11.72 Million USD | -67.29% |
| 2015 Q4 | -8.47 Million USD | -10.94% |
| 2015 FY | -27.86 Million USD | -131.38% |
| 2015 Q3 | -7.64 Million USD | -18.68% |
| 2015 Q2 | -6.44 Million USD | -21.56% |
| 2015 Q1 | -5.29 Million USD | -8.83% |
| 2014 Q4 | -4.86 Million USD | -73.67% |
| 2014 FY | -12.04 Million USD | -101.19% |
| 2014 Q1 | -2.25 Million USD | -46.6% |
| 2014 Q2 | -2.11 Million USD | 6.61% |
| 2014 Q3 | -2.8 Million USD | -32.83% |
| 2013 Q1 | -704.91 Thousand USD | 59.08% |
| 2013 Q4 | -1.54 Million USD | 43.11% |
| 2013 Q2 | -1.02 Million USD | -46.01% |
| 2013 Q3 | -2.7 Million USD | -163.2% |
| 2013 FY | -5.98 Million USD | 26.41% |
| 2012 Q4 | -1.72 Million USD | 0.0% |
| 2012 FY | -8.13 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -172.229% |
| Dynavax Technologies Corporation | -37.02 Million USD | -1143.813% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -8640.919% |
| Perrigo Company plc | 151.9 Million USD | 403.199% |
| Illumina, Inc. | -1.06 Billion USD | 56.917% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 106.715% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 96.728% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 123.296% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -316.362% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 111.38% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -931.095% |
| Waters Corporation | 817.67 Million USD | 156.325% |
| Biogen Inc. | 1.29 Billion USD | 135.515% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -68.084% |
| Evolus, Inc. | -49.23 Million USD | -835.468% |
| Adicet Bio, Inc. | -152.03 Million USD | -202.924% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -279.077% |
| bluebird bio, Inc. | -244.26 Million USD | -88.551% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -196.059% |
| FibroGen, Inc. | -281.81 Million USD | -63.426% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 134.115% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -921.709% |
| Homology Medicines, Inc. | -48.25 Million USD | -854.428% |
| Geron Corporation | -193.94 Million USD | -137.47% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -63.218% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -526.662% |
| Myriad Genetics, Inc. | -123.7 Million USD | -272.319% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -356.781% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 10.622% |
| Zoetis Inc. | 3.06 Billion USD | 115.007% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -855.517% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 142.359% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 336.863% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 110.692% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -1076.306% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -30.201% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -66.866% |
| Verastem, Inc. | -92.08 Million USD | -400.151% |
| Nektar Therapeutics | -137.42 Million USD | -235.135% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -98.667% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -373.062% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -71.963% |
| OPKO Health, Inc. | -157.02 Million USD | -193.31% |
| Exelixis, Inc. | 170.88 Million USD | 369.514% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 283.563% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 529.298% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -726.026% |
| uniQure N.V. | -282.87 Million USD | -62.816% |
| Imunon, Inc. | -21.03 Million USD | -2089.965% |
| Blueprint Medicines Corporation | -486.27 Million USD | 5.289% |
| Insmed Incorporated | -709.62 Million USD | 35.098% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 236.432% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | -17.643% |
| TG Therapeutics, Inc. | 20.63 Million USD | 2332.148% |
| Incyte Corporation | 620.52 Million USD | 174.221% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 36.597% |